More studies are needed to investigate the long-term effects of SGLT2i in these patients and to explore the pharmacological association, for instance, with GLP1RA, which has shown promising effects in kidney protection in people with T2DM and obesity, or mineralocorticoid receptor antagonists such as novel non-steroidal Finerenone. This evidence concerns the gene NR3C2 and obesity disorder.